secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-071992
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q1 net loss $21.2M ($0.35); cash $106.9M; MICVO data on track for H2 2025
--------------------------------------------------------------------------------

- Net loss $21.2M ($0.35/share) vs $3.3M ($0.06) in Q1 2024; prior year included $16.1M Novartis settlement revenue.
- Cash and investments $106.9M as of March 31, 2025; expected runway into second half of 2026.
- R&D expenses rose to $17.0M from $13.0M, driven by increased clinical and manufacturing costs for MICVO.
- On track to report Phase 1 monotherapy data for MICVO in HNSCC in H2 2025 and combination with pembrolizumab in H2 2025.
- Preclinical data confirm three-pronged mechanism of MICVO (direct killing, bystander effect, immunogenic cell death).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025071992/0000950170-25-071992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025071992/pyxs-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer